AVADEL PHARMACEUTICALS PLC's ticker is AVDL and the CUSIP is 05337M104. A total of 101 filers reported holding AVADEL PHARMACEUTICALS PLC in Q3 2023. The put-call ratio across all filers is 0.37 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $24,084,510 | -45.1% | 2,338,302 | -12.2% | 1.68% | -53.7% |
Q2 2023 | $43,903,972 | +28.4% | 2,664,076 | -28.6% | 3.64% | -9.4% |
Q1 2023 | $34,192,246 | +27.9% | 3,732,778 | 0.0% | 4.02% | +43.7% |
Q4 2022 | $26,726,690 | +42.9% | 3,732,778 | 0.0% | 2.79% | +56.2% |
Q3 2022 | $18,701,000 | +105.3% | 3,732,778 | 0.0% | 1.79% | +103.3% |
Q2 2022 | $9,108,000 | -64.3% | 3,732,778 | 0.0% | 0.88% | -64.1% |
Q1 2022 | $25,495,000 | -15.5% | 3,732,778 | 0.0% | 2.45% | -10.3% |
Q4 2021 | $30,161,000 | +21.9% | 3,732,778 | +47.8% | 2.74% | +133.2% |
Q3 2021 | $24,749,000 | +47.4% | 2,525,452 | +1.2% | 1.17% | +33.8% |
Q2 2021 | $16,795,000 | -25.6% | 2,495,573 | 0.0% | 0.88% | -43.5% |
Q1 2021 | $22,560,000 | +78.5% | 2,495,573 | +31.9% | 1.55% | +37.4% |
Q4 2020 | $12,639,000 | +31.6% | 1,892,043 | -0.7% | 1.13% | -28.0% |
Q3 2020 | $9,606,000 | -37.7% | 1,905,990 | -0.1% | 1.57% | -38.8% |
Q2 2020 | $15,413,000 | +43.2% | 1,907,504 | +25.7% | 2.56% | +3.6% |
Q1 2020 | $10,767,000 | – | 1,517,296 | – | 2.47% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
WEALTH EFFECTS LLC | 2,498,838 | $22,889,355 | 11.72% |
Knoll Capital Management, LLC | 500,000 | $4,580,000 | 7.06% |
GENDELL JEFFREY L | 5,301,914 | $48,565,532 | 4.55% |
COWEN AND COMPANY, LLC | 3,732,778 | $34,192,246 | 4.02% |
Tri Locum Partners LP | 1,327,097 | $12,156,209 | 3.70% |
Samsara BioCapital, LLC | 1,409,409 | $12,910,186 | 2.67% |
Altium Capital Management LP | 500,000 | $4,580,000 | 2.54% |
Vivo Capital, LLC | 3,761,438 | $34,454,772 | 2.39% |
RTW INVESTMENTS, LP | 5,741,939 | $52,596,161 | 1.10% |
Knott David M Jr | 291,113 | $2,667 | 1.05% |